CNS Pharmaceuticals (NASDAQ:CNSP) Trading 2.6% Higher – What’s Next?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) rose 2.6% during trading on Tuesday . The stock traded as high as $5.45 and last traded at $5.11. 19,407 shares changed hands during trading, an increase of 31% from the average daily volume of 14,831 shares. The stock had previously closed at $4.98.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Stock Up 2.6%

The firm has a market capitalization of $7.46 million, a P/E ratio of -0.17 and a beta of 3.06. The company’s 50 day moving average is $4.89 and its 200-day moving average is $4.34.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share for the quarter, beating the consensus estimate of ($8.82) by $1.52.

Insider Buying and Selling

In other news, Director Faith L. Charles bought 7,100 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average cost of $4.79 per share, with a total value of $34,009.00. Following the transaction, the director directly owned 7,100 shares of the company’s stock, valued at approximately $34,009. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.01% of the stock is owned by insiders.

Institutional Investors Weigh In On CNS Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals in the second quarter valued at approximately $335,000. Boothbay Fund Management LLC acquired a new position in shares of CNS Pharmaceuticals during the fourth quarter worth approximately $71,000. Finally, Ikarian Capital LLC bought a new position in shares of CNS Pharmaceuticals in the 4th quarter worth $241,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.